A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERα activation/repression and degradation in breast cancer cells
Authors:
- 13 March 2009
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 34 (4) , 939-949
Abstract
BRCA1 dysfunction is associated with hormone-responsive cancers. We have identified a consensus SUMO modification site in the amino-terminal region of BRCA1/1a/1b proteins and the mutation in this potential SUMO acceptor site (K 109 to R) impaired their ability to bind and repress ligand-dependent ERα transcriptional activity in breast cancer cells. Furthermore, we have found SUMO E2-conjugating enzyme Ubc9 to bind BRCA1 proteins. We have mapped BRCA1 [within amino acids (aa) 1-182] as the minimum domain that is sufficient for in vitro binding to Ubc9 as well as for regulating ERα activity. BRCA1 Mutant #1 (K109 to R) was impaired in its ability to both bind, as well as modulate Ubc9 mediated SUMO-dependent/independent E2-induced ERα transcriptional activity in breast cancer cells. Similarly, BRCA1 cancer-predisposing mutation (61Cys-Gly) abrogated the ability to both bind Ubc9 as well as inhibit ERα activity suggesting physiological significance. Addition of BRCA1 but not Mutant #1 to E2-induced ERα in the presence of SUMO-1 and Ubc9 resulted in the degradation of ERα suggesting BRCA1 to be a putative SUMO-1 and Ubc9-dependent E3 ubiquitin ligase for ERα. This is the first report demonstrating the participation of Ubc9 in BRCA1 E3 ubiquitin ligase mediated degradation of ERα. These results suggest a novel function for BRCA1 in regulating the dynamic cycles of SUMO and ubiquitin modifications required for ERα turn over and deregulation of this molecular switch due to lack of BRCA1 results in ERα-negative/positive breast cancers. This study will help in designing novel BRCA1 function-based targeted treatment for breast cancers.Keywords
This publication has 43 references indexed in Scilit:
- SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancyNucleic Acids Research, 2007
- Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteinsThe EMBO Journal, 2007
- Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligaseProceedings of the National Academy of Sciences, 2007
- Basal-like breast cancer and the BRCA1 phenotypeOncogene, 2006
- Ubiquitin and breast cancerOncogene, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Role of direct interaction in BRCA1 inhibition of estrogen receptor activityOncogene, 2001
- Expression Profiles of BRCA1 Splice Variants in Asynchronous and in G1/S Synchronized Tumor Cell LinesBiochemical and Biophysical Research Communications, 2001
- BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinasesOncogene, 1997
- Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlationNature Genetics, 1995